Live Yum Brands Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ProPhase Labs, Inc.

Get SEC filing alerts via email and in your feed for ProPhase Labs, Inc.

PRPH

ProPhase Labs, Inc.

About ProPhase Labs, Inc.

ProPhase Labs is a diversified biotech and genomics company developing and commercializing drugs, dietary supplements, and human genomic testing services. Its core segments include genetic sequencing via Nebula Genomics, drug development through ProPhase BioPharma, and consumer health products under TK Supplements. The company focuses on early disease detection, personalized medicine, and health optimization, serving healthcare providers, consumers, and research institutions worldwide with innovative diagnostics and genomic solutions.
This description was generated via AI from an annual report. Updated 10 months ago.

Latest SEC Filings from ProPhase Labs, Inc.

1
1
ProPhase Labs, Inc. ProPhase Labs Reports Significant Revenue Decline and Increased Net Loss in Q1 2026

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
ProPhase Labs, Inc. ProPhase Labs Reports 35.8% Revenue Decline and $14.7 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | about 2 months ago | 0 comments

3
1
ProPhase Labs, Inc. ProPhase Labs Reports 38% Revenue Decline and $6.8 Million Net Loss in Q3 2025

Via official filing (AI summary) | 8 months ago | 0 comments

4
1
ProPhase Labs, Inc. ProPhase Labs Reports Q2 2025 Financial Results with Revenue Decline and Strategic Shift

Via official filing (AI summary) | 11 months ago | 0 comments

5
1
ProPhase Labs, Inc. ProPhase Labs Reports $1.4 Million Revenue in Q1 2025, Net Loss Improves

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ProPhase Labs, Inc. ProPhase Labs Reports 80.6% Revenue Decline and Strategic Shift Following Sale of Subsidiary

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
ProPhase Labs, Inc. ProPhase Labs Reports Significant Revenue Decline and Increased Losses for Q3 and Nine Months Ended September 30, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments